Gilead Sciences Quarterly Income Statement
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gilead Sciences revenue and earnings
In the quarter ended Jun 30, 2026, Gilead Sciences generated $7.80 billion in revenue, up 10.2% from the same quarter a year earlier. Gilead Sciences reported a net loss of $10.50 billion, compared with net income of $1.96 billion a year earlier. Gross margin was 79.8% (up from 78.8%) and operating margin -133.2%.
Diluted earnings per share came in at -$8.45, down from $1.56.
Summary generated from market data by MetaCap's automated system. Methodology
Gilead Sciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.80B | 6.96B | 7.92B | 7.77B | 7.08B | 6.67B | 7.57B | 7.54B | 6.95B | 6.69B | 7.11B | 7.05B |
| Revenue growth (YoY) | +10.18% | +4.39% | +4.70% | +2.97% | +1.84% | -0.28% | +6.40% | +7.01% | +5.38% | +5.26% | -3.72% | +0.13% |
| Cost of Revenue | 1.58B | 1.45B | 1.62B | 1.57B | 1.50B | 1.54B | 1.58B | 1.57B | 1.54B | 1.55B | 2.09B | 1.56B |
| Gross Profit | 6.22B | 5.51B | 6.30B | 6.20B | 5.58B | 5.13B | 5.99B | 5.97B | 5.41B | 5.13B | 5.02B | 5.49B |
| Operating Expenses | 16.62B | 2.93B | 4.32B | 2.87B | 3.11B | 2.89B | 3.54B | 5.08B | 2.77B | 9.46B | 3.41B | 2.86B |
| Research & Development | 1.76B | 1.37B | 1.58B | 1.35B | 1.49B | 1.38B | 1.64B | 1.40B | 1.35B | 1.52B | 1.41B | 1.46B |
| Selling, General & Admin | 1.92B | 1.45B | 1.79B | 1.36B | 1.36B | 1.26B | 1.91B | 1.43B | 1.38B | 1.38B | 1.61B | 1.31B |
| Operating Income | -10.39B | 2.59B | 1.98B | 3.33B | 2.47B | 2.24B | 2.45B | 888.00M | 2.64B | -4.32B | 1.61B | 2.62B |
| Interest Expense | 247.00M | 240.00M | 255.00M | 256.00M | 254.00M | 260.00M | 249.00M | 238.00M | 237.00M | 254.00M | 252.00M | 232.00M |
| Other Income (Expense) | 387.00M | 235.00M | 349.00M | 569.00M | 208.00M | -328.00M | -35.00M | 306.00M | -355.00M | 91.00M | 293.00M | -72.00M |
| Pretax Income | -10.25B | 2.58B | 2.08B | 3.64B | 2.43B | 1.65B | 2.17B | 956.00M | 2.05B | -4.49B | 1.65B | 2.32B |
| Income Tax | 242.00M | 559.00M | -105.00M | 589.00M | 468.00M | 334.00M | 385.00M | -297.00M | 438.00M | -315.00M | 237.00M | 146.00M |
| Net Income | -10.50B | 2.02B | 2.18B | 3.05B | 1.96B | 1.31B | 1.78B | 1.25B | 1.61B | -4.17B | 1.43B | 2.18B |
| Net Income growth (YoY) | -635.51% | +53.69% | +22.43% | +143.58% | +21.44% | — | +24.77% | -42.52% | +54.45% | -512.87% | -12.87% | +21.86% |
| EPS (Basic) | -8.45 | 1.63 | 1.75 | 2.46 | 1.57 | 1.06 | 1.43 | 1.00 | 1.29 | -3.34 | 1.14 | 1.75 |
| EPS (Diluted) | -8.45 | 1.61 | 1.75 | 2.43 | 1.56 | 1.04 | 1.43 | 1.00 | 1.29 | -3.34 | 1.14 | 1.73 |
| Shares Outstanding (Basic) | 1.24B | 1.24B | — | 1.24B | 1.25B | 1.25B | — | 1.25B | 1.25B | 1.25B | — | 1.25B |
| Shares Outstanding (Diluted) | 1.24B | 1.25B | — | 1.25B | 1.25B | 1.26B | — | 1.25B | 1.25B | 1.25B | — | 1.26B |
| EBITDA | -10.30B | 2.68B | 2.07B | 3.42B | 2.57B | 2.33B | 2.55B | 982.00M | 2.74B | -4.23B | 1.70B | 2.71B |
| Gross Margin | 79.76% | 79.24% | 79.51% | 79.80% | 78.81% | 76.90% | 79.11% | 79.14% | 77.80% | 76.79% | 70.62% | 77.80% |
| Operating Margin | -133.21% | 37.16% | 25.03% | 42.82% | 34.93% | 33.55% | 32.40% | 11.77% | 38.02% | -64.64% | 22.66% | 37.20% |
| Net Margin | -134.51% | 29.04% | 27.55% | 39.28% | 27.68% | 19.72% | 23.56% | 16.61% | 23.21% | -62.37% | 20.09% | 30.92% |
This table shows 12 quarterly periods of Gilead Sciences's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow GILD's reporting calendar. What is a income statement?